Alumis' lead drug, ESK-001, is a potential best-in-class TYK2 inhibitor for treating plaque psoriasis and immunological diseases in general., with phase 3 trial data expected in 1H2026. With ...

Alumis's lead product candidate, ESK-001, has shown promising results in a Phase 2 psoriasis study and is expected to generate multi-billion dollar revenues if approved.

Alumis Inc. focuses on TYK2 inhibitors ESK-001 and A-005, with ESK-001 in Phase 3 for plaque psoriasis. Find out why ALMS stock is a sell.

Alumis Inc. completed patient enrollment in its Phase 3 trials for ESK-001, targeting moderate-to-severe plaque psoriasis. Quiver AI Summary. Alumis Inc. has announced the successful completion of ...

Alumis is making up some of that by selling 2.5 million shares at the IPO price to one of its largest investors. This concurrent private placement brings Alumis an additional $40 million.

Alumis Inc. – Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy ...

Alumis is also developing A-005, a CNS-penetrant, allosteric TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases. Beyond TYK2, ...

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to ...

June 28 (Reuters) - Shares of biopharmaceutical firm Alumis (ALMS.O), opens new tab opened nearly 16% below their initial public offering (IPO) price in their debut on the Nasdaq on Friday. A long ...

Shares of Alumis Inc. fell 17% in their trading debut after the clinical stage biopharmaceutical company raised $250 million in a downsized initial public offering with a concurrent private placement.

SOUTH SAN FRANCISCO, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (“Alumis” or the “Company”) (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies ...